Editorial: Rising stars in cancer immunity and immunotherapy 2022

Cleo Goyvaerts; Christine E Engeland; Kevin Van der Jeught

doi:10.3389/fimmu.2023.1326374

Editorial: Rising stars in cancer immunity and immunotherapy 2022

Front Immunol. 2023 Nov 7:14:1326374. doi: 10.3389/fimmu.2023.1326374. eCollection 2023.

Authors

Cleo Goyvaerts¹, Christine E Engeland², Kevin Van der Jeught^{3

4}

Affiliations

¹ Laboratory for Molecular and Cellular Therapy, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Brussels, Belgium.
² Experimental Hematology and Immunotherapy, Department of Hematology, Hemostaseology, Cellular Therapy and Infectious Diseases, Faculty of Medicine and Leipzig University Hospital, Leipzig, Germany.
³ Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, United States.
⁴ Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States.

No abstract available

Keywords: adoptive cell therapies; immune checkpoint inhibition; immunotherapy; microbiome; oncolytic virotherapy; perioperative activity; personalized medicine.

Publication types

Editorial

MeSH terms

Humans
Immunotherapy
Neoplasms* / therapy

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.